Curcumin (diferuloylmethane), a yellow pigment in the spice turmeric (also called curry powder), has been used for centuries as a treatment for inflammatory diseases.
Extensive research within the past two decades has shown that curcumin mediates its anti-inflammatory effects through the downregulation of:
• Inflammatory transcription factors (such as nuclear factor kappaB),
• Enzymes (such as cyclooxygenase 2 and 5 lipoxygenase)
• And cytokines (such as tumor necrosis factor, interleukin 1 and interleukin 6).
Because of the crucial role of inflammation in most chronic diseases, the potential of curcumin has been examined in neoplastic [tumorous], neurological, cardiovascular, pulmonary and metabolic diseases.
The pharmacodynamics and pharmacokinetics of curcumin have been examined in animals and in humans.
Various pharmacological aspects of curcumin in vitro [lab] and in vivo [living subjects] are discussed in detail here.
Source: Trends in Pharmacological Sciences, Feb 2009;30(2):85-94. PMID: 19110321 by Aggarwal BB, Sung B. Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. [E-mail: firstname.lastname@example.org]